InflaRx (IFRX) to Release Earnings on Thursday

Key Points

• InflaRx is set to announce its Q2 2025 earnings on August 7th, with analysts predicting a loss of ($0.24) per share and revenue of $0.02 million.
• The company's stock has seen a decline of 5.0%, currently trading at $0.86, significantly lower than its 12-month high of $2.82.
• Analysts have varied opinions on InflaRx's stock, with Oppenheimer lowering its price target from $6.00 to $3.00 while Cantor Fitzgerald set an overweight rating with a target of $10.00.

InflaRx (NASDAQ:IFRX - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, August 7th. Analysts expect InflaRx to post earnings of ($0.24) per share and revenue of $0.02 million for the quarter.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

InflaRx Stock Down 5.0%

NASDAQ IFRX opened at $0.86 on Friday. The company's 50 day moving average is $0.88 and its 200-day moving average is $1.37. InflaRx has a 12-month low of $0.71 and a 12-month high of $2.82. The firm has a market cap of $57.73 million, a P/E ratio of -1.05 and a beta of 1.29.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. Oppenheimer lowered their price target on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a research report on Thursday, May 29th. Cantor Fitzgerald assumed coverage on shares of InflaRx in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target on the stock. Finally, Raymond James Financial lowered shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 price target on the stock. in a research report on Thursday, May 29th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, InflaRx currently has a consensus rating of "Buy" and an average price target of $6.60.

Institutional Trading of InflaRx

An institutional investor recently bought a new position in InflaRx stock. Woodline Partners LP bought a new position in shares of InflaRx N.V. (NASDAQ:IFRX - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 750,984 shares of the company's stock, valued at approximately $766,000. Woodline Partners LP owned 1.12% of InflaRx at the end of the most recent quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.